Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rain Oncology Inc.RAIN · Entity 94695 | Director | January 26, 2024 | January 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rain Oncology Inc.
Report date January 26, 2024 · Filed January 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-26 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.91 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-26 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nurix Therapeutics, Inc.
Report date April 30, 2023 · Filed May 02, 2023
Section 16 reporting ended · disclosed 2023-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,113 |
Last balance in matching sequence
After 2023-05-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-04-30 · Exercise / conversion · Acquired 962 · Balance 6,455 F1: Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan. Row 2 · 2023-05-01 · Sale · Disposed 342 · Balance 6,113 F2: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3: Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. F1: Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,582 |
Reported balance
After 2023-04-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-30 · Exercise / conversion · Disposed 962 · Balance 10,582 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F6: RSUs do not expire; they either vest or are canceled prior to the vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan.
F2: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3: Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
F6: RSUs do not expire; they either vest or are canceled prior to the vest date.
Principia Biopharma Inc.
Report date September 28, 2020 · Filed September 28, 2020
Section 16 reporting ended · disclosed 2020-09-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-09-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-09-18 · Gift · Disposed 5,504 · Balance 13,592 Row 2 · 2020-09-28 · Other · Disposed 13,592 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.54 · Expires 2027-02-15 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-09-28 · Disposition to issuer · Disposed 30,056 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2027-12-13 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-09-28 · Disposition to issuer · Disposed 16,843 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.35 · Expires 2028-08-23 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-09-28 · Disposition to issuer · Disposed 22,017 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2028-08-27 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-09-28 · Disposition to issuer · Disposed 55,042 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.31 · Expires 2030-03-04 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-09-28 · Disposition to issuer · Disposed 55,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2024 Filed Jan 26, 2024 16:50 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001999371-24-000976 · ownership.xml · derivative · entry 3 Wolff Stefani · CIK 0001751790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:50 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,000 | Not disclosed Strike: $15.91 | Not disclosed |
DisclosureSEC source: 0001999371-24-000976 · ownership.xml · derivative · entry 2 Wolff Stefani · CIK 0001751790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:50 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001999371-24-000976 · ownership.xml · derivative · entry 1 Wolff Stefani · CIK 0001751790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 21:09 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001104659-23-090700 · tm2323614-5_4seq1.xml · derivative · entry 1 Wolff Stefani · CIK 0001751790 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: This option represents a right to purchase a total of 35,000 shares of the Issuer's common stock, which will vest in full on the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 01, 2023 Filed May 2, 2023 16:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 342 | $9.88 | $3,377.69 |
DisclosureSEC source: 0001209191-23-026527 · doc4.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,113 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. F1 · balance_after: Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| April 30, 2023 Filed May 2, 2023 16:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 962 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026527 · doc4.xml · derivative · entry 3 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,582 Underlying: Common Stock · 962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2023 Filed May 2, 2023 16:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 962 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026527 · doc4.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 16:14 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 24,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009712 · doc4.xml · derivative · entry 2 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on April 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 16:14 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 88,900 | $0.00 Strike: $10.83 | $0.00 |
DisclosureSEC source: 0001209191-23-009712 · doc4.xml · derivative · entry 1 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,900 Underlying: Common Stock · 88,900 shares Expires 2033-02-13 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 14, 2023 until the option is fully vested on February 14, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:18 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 962 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005910 · doc4.xml · derivative · entry 3 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,544 Underlying: Common Stock · 962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:18 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 424 | $11.78 | $4,994.55 |
DisclosureSEC source: 0001209191-23-005910 · doc4.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,940 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.60 and the highest price at which shares were sold was $12.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:18 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 962 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005910 · doc4.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 19:32 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 350 | $12.88 | $4,508.18 |
DisclosureSEC source: 0001209191-22-055136 · doc4.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,402 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.76 and the highest price at which shares were sold was $12.99. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 30, 2022 Filed Nov 1, 2022 19:32 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 962 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055136 · doc4.xml · derivative · entry 3 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,506 Underlying: Common Stock · 962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2022 Filed Nov 1, 2022 19:32 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 962 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055136 · doc4.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,552 shares of Common Stock acquired by the Reporting Person on August 15, 2022 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 16:18 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 110,375 | $0.00 Strike: $18.50 | $0.00 |
DisclosureSEC source: 0001209191-22-045196 · doc4.xml · derivative · entry 1 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,375 Underlying: Common Stock · 110,375 shares Expires 2032-08-08 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning September 9, 2022 until the option is fully vested on August 9, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 17:48 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 356 | $15.67 | $5,578.52 |
DisclosureSEC source: 0001209191-22-043963 · doc4.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,238 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $15.32 and the highest price at which shares were sold was $16.01. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 30, 2022 Filed Aug 2, 2022 17:48 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 962 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043963 · doc4.xml · derivative · entry 3 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,468 Underlying: Common Stock · 962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2022 Filed Aug 2, 2022 17:48 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 962 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-043963 · doc4.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Aug 19, 2022 17:38 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0000899243-22-029316 · doc4.xml · derivative · entry 1 Wolff Stefani · CIK 0001751790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's common stock, which will vest in full on June 1, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 02, 2022 Filed May 3, 2022 19:04 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 330 | $11.75 | $3,877.50 |
DisclosureSEC source: 0001209191-22-026891 · doc4.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 30, 2022 Filed May 3, 2022 19:04 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 962 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026891 · doc4.xml · derivative · entry 3 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,430 Underlying: Common Stock · 962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2022 Filed May 3, 2022 19:04 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 962 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026891 · doc4.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 16:17 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 15,392 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-004409 · doc4.xml · derivative · entry 2 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,392 Underlying: Common Stock · 15,392 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 16:17 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 34,631 | $0.00 Strike: $19.49 | $0.00 |
DisclosureSEC source: 0001209191-22-004409 · doc4.xml · derivative · entry 1 Wolff Stefani · CIK 0001751790 · EVP and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,631 Underlying: Common Stock · 34,631 shares Expires 2032-01-18 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning February 19, 2022 until the option is fully vested on January 19, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 14, 2021 Filed May 18, 2021 17:44 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $15.33 | $0.00 |
DisclosureSEC source: 0000899243-21-019787 · doc4.xml · derivative · entry 1 Wolff Stefani · CIK 0001751790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 24,000 shares of the Issuer's common stock, which will vest in equal monthly installments through May 14, 2024, subject to the Reporting Person's continued service to the Issuer.. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:19 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 55,000 | Not disclosed Strike: $67.31 | Not disclosed |
DisclosureSEC source: 0001209191-20-052227 · doc4.xml · derivative · entry 8 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2030-03-04 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:19 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $35.42 | Not disclosed |
DisclosureSEC source: 0001209191-20-052227 · doc4.xml · derivative · entry 7 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2029-02-28 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:19 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 55,042 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-20-052227 · doc4.xml · derivative · entry 6 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,042 shares Expires 2028-08-27 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:19 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 22,017 | Not disclosed Strike: $11.35 | Not disclosed |
DisclosureSEC source: 0001209191-20-052227 · doc4.xml · derivative · entry 5 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,017 shares Expires 2028-08-23 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:19 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 16,843 | Not disclosed Strike: $7.27 | Not disclosed |
DisclosureSEC source: 0001209191-20-052227 · doc4.xml · derivative · entry 4 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,843 shares Expires 2027-12-13 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:19 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 30,056 | Not disclosed Strike: $4.54 | Not disclosed |
DisclosureSEC source: 0001209191-20-052227 · doc4.xml · derivative · entry 3 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,056 shares Expires 2027-02-15 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:19 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | OtherCommon Stock | 13,592 | $100.00 | $1,359,200.00 |
DisclosureSEC source: 0001209191-20-052227 · doc4.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document |
| September 18, 2020 Filed Sep 28, 2020 17:19 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | GiftCommon Stock | 5,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052227 · doc4.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,592 Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 21:52 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 100 | $61.37 | $6,136.80 |
DisclosureSEC source: 0001209191-20-037486 · doc4.xml · nonDerivative · entry 3 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,096 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 21:52 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 5,004 | $60.81 | $304,290.74 |
DisclosureSEC source: 0001209191-20-037486 · doc4.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,196 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $60.20 to $61.17 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 21:52 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 400 | $59.89 | $23,957.00 |
DisclosureSEC source: 0001209191-20-037486 · doc4.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,200 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $59.18 to $60.13 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 17:08 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,504 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001209191-20-020043 · doc4.xml · derivative · entry 4 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,047 Underlying: Common Stock · 5,504 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on July 1, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 17:08 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 3,750 | $46.36 | $173,838.38 |
DisclosureSEC source: 0001209191-20-020043 · doc4.xml · nonDerivative · entry 3 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,609 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $46.08 to $46.60 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 17:08 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 1,754 | $45.72 | $80,192.18 |
DisclosureSEC source: 0001209191-20-020043 · doc4.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,359 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $45.05 to $46.01 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 17:08 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Exercise / conversionCommon Stock | 5,504 | $4.54 | $24,999.17 |
DisclosureSEC source: 0001209191-20-020043 · doc4.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2020 Filed Jun 17, 2020 21:48 UTC Amendment | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 3,750 | $46.36 | $173,838.38 |
DisclosureSEC source: 0001209191-20-037484 · doc4a.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,600 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $46.08 to $46.60 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| March 16, 2020 Filed Jun 17, 2020 21:48 UTC Amendment | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 1,754 | $45.72 | $80,192.18 |
DisclosureSEC source: 0001209191-20-037484 · doc4a.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,350 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $45.05 to $46.01 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Due to administrative error, stock options were incorrectly reported as exercised on the original Form 4 filed on March 18, 2020, pursuant to a 10b5-1 transaction. That original Form 4 is hereby amended in its entirety. Read SEC document |
| March 05, 2020 Filed Mar 5, 2020 17:30 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | GrantEmployee Stock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $67.31 | $0.00 |
DisclosureSEC source: 0001209191-20-016696 · doc4.xml · derivative · entry 1 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-03-04 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 5, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 19:09 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,505 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001209191-19-061189 · doc4.xml · derivative · entry 4 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,551 Underlying: Common Stock · 5,505 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on July 1, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 19:09 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 1,300 | $49.87 | $64,825.02 |
DisclosureSEC source: 0001209191-19-061189 · doc4.xml · nonDerivative · entry 3 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,609 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $49.855 to $49.87 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 19:09 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 4,205 | $49.29 | $207,265.71 |
DisclosureSEC source: 0001209191-19-061189 · doc4.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,909 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $48.81 to $49.725 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 19:09 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Exercise / conversionCommon Stock | 5,505 | $4.54 | $25,003.71 |
DisclosureSEC source: 0001209191-19-061189 · doc4.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,500 shares and 441 shares acquired under the Employment Stock Purchase Plan on May 15, 2019 and November 15, 2019 respectively. Read SEC document |
| December 16, 2019 Filed Jun 17, 2020 21:41 UTC Amendment | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 1,300 | $49.87 | $64,825.02 |
DisclosureSEC source: 0001209191-20-037483 · doc4a.xml · nonDerivative · entry 2 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,104 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $49.855 to $49.87 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 16, 2019 Filed Jun 17, 2020 21:41 UTC Amendment | Principia Biopharma Inc. PRNB · Entity 146423 | SaleCommon Stock | 4,205 | $49.29 | $207,265.71 |
DisclosureSEC source: 0001209191-20-037483 · doc4a.xml · nonDerivative · entry 1 Wolff Stefani · CIK 0001751790 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,404 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $48.81 to $49.725 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · balance_after: Includes 2,500 shares and 441 shares acquired under the Employment Stock Purchase Plan on May 15, 2019 and November 15, 2019 respectively. F4 · balance_after: Due to administrative error, stock options were incorrectly reported as exercised on the original Form 4 filed on December 18, 2019, pursuant to a 10b5-1 transaction. That original Form 4 is hereby amended in its entirety. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.